BCDA BioCardia Inc

Price (delayed)

$1.42

Market cap

$24.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.76

Enterprise value

$16.68M

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's ...

Highlights
The EPS has grown by 30% YoY
BioCardia's net income has increased by 3% YoY but it has decreased by 2.8% from the previous quarter
The equity has dropped by 60% year-on-year and by 29% since the previous quarter
BCDA's quick ratio is down by 44% YoY and by 25% from the previous quarter

Key stats

What are the main financial stats of BCDA
Market
Shares outstanding
17.45M
Market cap
$24.77M
Enterprise value
$16.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.25
Price to sales (P/S)
23.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.21
Earnings
Revenue
$1.03M
EBIT
-$12.98M
EBITDA
-$12.98M
Free cash flow
-$11.51M
Per share
EPS
-$0.76
Free cash flow per share
-$0.67
Book value per share
$0.44
Revenue per share
$0.06
TBVPS
$0.75
Balance sheet
Total assets
$12.84M
Total liabilities
$5.47M
Debt
$1.84M
Equity
$7.37M
Working capital
$6.75M
Liquidity
Debt to equity
0.25
Current ratio
2.72
Quick ratio
2.62
Net debt/EBITDA
0.62
Margins
EBITDA margin
-1,261.5%
Gross margin
100%
Net margin
-1,261.3%
Operating margin
-1,261.9%
Efficiency
Return on assets
-78.5%
Return on equity
-110.9%
Return on invested capital
N/A
Return on capital employed
-145.4%
Return on sales
-1,261.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCDA stock price

How has the BioCardia stock price performed over time
Intraday
-3.4%
1 week
0%
1 month
-8.39%
1 year
-68.37%
YTD
-26.8%
QTD
-31.4%

Financial performance

How have BioCardia's revenue and profit performed over time
Revenue
$1.03M
Gross profit
$1.03M
Operating income
-$12.99M
Net income
-$12.98M
Gross margin
100%
Net margin
-1,261.3%
BioCardia's operating margin has surged by 86% YoY
The net margin has surged by 86% year-on-year
BioCardia's operating income has increased by 7% YoY but it has decreased by 2.8% from the previous quarter
BioCardia's net income has increased by 3% YoY but it has decreased by 2.8% from the previous quarter

Growth

What is BioCardia's growth rate over time

Valuation

What is BioCardia stock price valuation
P/E
N/A
P/B
3.25
P/S
23.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.21
The EPS has grown by 30% YoY
BCDA's P/B is 73% below its 5-year quarterly average of 12.1 and 19% below its last 4 quarters average of 4.0
The equity has dropped by 60% year-on-year and by 29% since the previous quarter
BCDA's P/S is 86% below its 5-year quarterly average of 162.9 and 80% below its last 4 quarters average of 117.1

Efficiency

How efficient is BioCardia business performance
The ROS has soared by 86% YoY
The company's return on equity fell by 27% QoQ
The ROA has contracted by 19% from the previous quarter

Dividends

What is BCDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCDA.

Financial health

How did BioCardia financials performed over time
BCDA's total assets is 135% higher than its total liabilities
BCDA's total assets is down by 45% YoY and by 18% QoQ
BCDA's quick ratio is down by 44% YoY and by 25% from the previous quarter
The debt is 75% smaller than the equity
The equity has dropped by 60% year-on-year and by 29% since the previous quarter
BioCardia's debt to equity has increased by 39% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.